重组人红细胞生成素联合铁制剂治疗维持性血液透析患者疗效观察

摘要

Objective To study the effect of recombinant human erythropoietin and iron preparations on maintenance hemodialysis patients .Methods One hundred and twenty hemodialysis patients were included in the study; They were ran-domly divided into 2 groups , 60 cases in each group:recombinant human erythropoietin and iron preparations for the observa-tion group, recombinant human erythropoietin treatment for the control group , treatment lasted for 10 weeks.After that, blood indexes, therapeutic effect, quality of life were compared between the 2 groups of patients.Results (1) Clinical effect:the total effective rate of observation group was 76.7%, significantly higher than that in control group 60.0%( P <0.05);(2) The blood index:compared with before treatment , the observation group of hemoglobin ( Hb) , hematocrit ( HCT) , serum iron (SI), serum ferritin (SF), transferrin saturation (TSAT), total iron binding capacity (TIBC), C reactive protein (CRP) were significantly improved ( P <0.05, P <0.01), and higher than that of control group ( P <0.05, P <0.01); Hb, HCT, TIBC in the control group improved significantly ( P <0.05), the other indexes were not improved statistically signifi-cant ( P >0.05);(3) Quality of life: compared with before treatment , the patients in observation group's self-realization, health responsibility, exercise, nutrition, interpersonal relationship, managing stress scores were increased significantly , and higher than that of control group ( P <0.05);in the control group, sports and nutrition had no significant difference ( P >0.05), others had statistical significance ( P <0.05, P <0.01).Conclusion Recombinant human erythropoietin and iron preparations for the treatment of patients with maintenance hemodialysis can helps to promote blood , improve anemia , improve the quality of life , but the assessment of iron metabolism indices should be to strengthen in the course of treatment .%目的：研究重组人红细胞生成素联合铁制剂治疗维持性血液透析患者的临床疗效。方法将进行血液透析治疗的患者120例纳入研究对象，采用数字表法随机分为2组各60例：重组人红细胞生成素联合铁制剂治疗为观察组，仅给予重组人红细胞生成素治疗为对照组，治疗10周后，比较2组患者的血液指标、治疗效果、生存质量。结果（1）临床疗效：观察组总有效率为76耨．7％，明显高于对照组的60．0％（ P ＜0．05）；（2）血液指标：与治疗前比较，观察组血红蛋白（Hb）、红细胞压积（HCT）、血清铁（SI）、血清铁蛋白（SF）、转铁蛋白饱和度（TSAT）、总铁结合力（TIBC）、C反应蛋白（CRP）均明显改善（ P ＜0．05， P ＜0．01），且高于对照组（ P ＜0．05， P ＜0．01）；而对照组除Hb、HCT、TIBC改善明显（ P ＜0．05），其他指标差异均无统计学意义（ P ＞0．05）；（3）生存质量：与治疗前比较，观察组患者的自我实现、健康责任、运动、营养、人际关系、应对压力等评分均明显升高，且高于对照组（ P ＜0．05）；对照组除运动、营养2项差异无统计学意义（ P ＞0．05），其他几项差异均有统计学意义（ P ＜0．05， P ＜0．01）。结论重组人红细胞生成素联合铁制剂治疗维持性血液透析患者，有助于促进造血、改善贫血、提高整体生存质量，但在治疗过程中应加强对铁代谢指标的评估。